TP53 and neoplasm: In Ansari-Pour et al.’s Nigerian cohorts (Fig. 6), within-cohort analyses revealed TP53 enrichment in ER– tumours, sustained GATA3 enrichment after adjusting for receptor status, and higher HRD-signature activity in TNBC versus other subtypes—yet no cross-cohort, subtype-matched comparison was performed.